“Wet AMD causes aberrant blood vessels to form beneath the macula and retina. These aberrant blood vessels may bleed or leak fluid, causing the macula to expand or push up from its normal location and cause serious vision loss. The rising prevalence of AMD and the growing senior population are two significant factors driving the growth of the wet age-related macular degeneration market. The global burden of AMD continues to climb at an unprecedented rate as the global population grows and the demographics reflect a majority of older people. AMD is the third most common cause of severe visual impairment, which can lead to blindness. AMD is predicted to become more common as the world’s population ages, with a higher frequency in Western countries.
In the wet age-related macular degeneration market, the emerging market for wet AMD in Asia-Pacific (APAC) and potential alternate therapies can be regarded as significant opportunities. The APAC region offers a plethora of potential for competitors in the wet age-related macular degeneration market to expand. The sale of medications for exudative AMD in APAC is currently insignificant due to a lack of accessibility and expensive drug costs. The region, however, has a high prevalence of AMD, making it a potentially growing market. Furthermore, in APAC, the presence of companies involved in the marketing and research of exudative AMD medicines is fairly low.
Top company of Wet Age-Related Macular Degeneration (Wet AMD) Market:
F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceutical Inc., Pfizer Inc., Bayer AG, Ophthotech Corporation, GlaxoSmithKline plc, Neurotech Pharmaceuticals Inc., Alimera Sciences Inc., StemCells Inc. & Others.
Request Sample here for more Information or Any Query Visit
Wet Age-Related Macular Degeneration (Wet AMD) Market Segmentation and Market Scope:
(Wet Age-Related Macular Degeneration (Wet AMD)
Dry Age-Related Macular Degeneration
(Intermediate Stage Age-Related Macular Degeneration, Early-Stage Age-Related Macular Degeneration and Late Stage Age-Related Macular Degeneration)
(Above 75 years, Above 60 years and Above 40 years)
(Treatment and Diagnosis)
Route of Administration
(Intravitreal Route of Administration and Intravenous Route of Administration)
(Hospital & Clinics, Diagnostic Centers and Academic Research Institutes)
At what CAGR, the Wet Age-Related Macular Degeneration (Wet AMD) market is expected to grow during the forecast period (2021–2027)?
What would be the wet Age-Related Macular Degeneration (Wet AMD) market outlook during the forecast period (2021–2027)?
What would be the Wet Age-Related Macular Degeneration (Wet AMD) market growth till 2027 and what will be the resultant market size in the year 2027?
How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
If you need anything more than these then let us know and we will prepare the report according to your requirement.
International : +1 518 300 3575